Clearview Wealth Advisors LLC Sells 138 Shares of Abbott Laboratories (NYSE:ABT)

Clearview Wealth Advisors LLC lessened its stake in shares of Abbott Laboratories (NYSE:ABT) by 4.6% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,845 shares of the healthcare product maker’s stock after selling 138 shares during the period. Clearview Wealth Advisors LLC’s holdings in Abbott Laboratories were worth $296,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. Unique Wealth Strategies LLC bought a new position in shares of Abbott Laboratories in the second quarter valued at $28,000. Signature Resources Capital Management LLC bought a new position in shares of Abbott Laboratories in the 4th quarter valued at about $29,000. Redmont Wealth Advisors LLC acquired a new position in shares of Abbott Laboratories during the 1st quarter worth about $30,000. Richardson Financial Services Inc. bought a new stake in shares of Abbott Laboratories in the 4th quarter valued at about $29,000. Finally, Transcendent Capital Group LLC acquired a new stake in Abbott Laboratories in the 4th quarter valued at about $29,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Price Performance

NYSE ABT traded up $0.51 during trading on Friday, hitting $113.27. 4,320,139 shares of the company’s stock were exchanged, compared to its average volume of 5,114,636. The company has a market cap of $197.08 billion, a PE ratio of 35.29, a P/E/G ratio of 2.82 and a beta of 0.72. The company has a current ratio of 1.68, a quick ratio of 1.18 and a debt-to-equity ratio of 0.33. The stock’s 50 day moving average price is $106.97 and its two-hundred day moving average price is $108.74. Abbott Laboratories has a fifty-two week low of $89.67 and a fifty-two week high of $121.64.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, July 18th. The healthcare product maker reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.04. The company had revenue of $10.38 billion during the quarter, compared to the consensus estimate of $10.37 billion. Abbott Laboratories had a net margin of 13.65% and a return on equity of 20.18%. The company’s revenue for the quarter was up 4.0% compared to the same quarter last year. During the same period in the prior year, the business earned $1.08 earnings per share. Research analysts expect that Abbott Laboratories will post 4.66 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, August 15th. Investors of record on Monday, July 15th were given a dividend of $0.55 per share. The ex-dividend date of this dividend was Monday, July 15th. This represents a $2.20 annualized dividend and a yield of 1.94%. Abbott Laboratories’s dividend payout ratio is presently 68.54%.

Analyst Ratings Changes

Several analysts have issued reports on the company. Edward Jones lowered Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday, July 30th. Citigroup raised their price target on Abbott Laboratories from $119.00 to $127.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. The Goldman Sachs Group started coverage on Abbott Laboratories in a report on Thursday, May 30th. They set a “buy” rating and a $121.00 price objective for the company. Royal Bank of Canada reiterated an “outperform” rating and set a $125.00 target price on shares of Abbott Laboratories in a research note on Tuesday, June 4th. Finally, Barclays boosted their price target on Abbott Laboratories from $140.00 to $143.00 and gave the company an “overweight” rating in a research note on Monday, July 29th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, Abbott Laboratories currently has an average rating of “Moderate Buy” and an average price target of $121.80.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.